Dina Khalaf, Talent Acquisition Partner at Gowrie NSW, shared a post on LinkedIn:
“Our systematic review and meta-analysis presented at the 67th ASH Annual Meeting (2025) examining how race, ethnicity, and socioeconomic status affect survival and treatment outcomes in acute myeloid leukemia (AML).
The outcomes emphasize that the very small number of directly comparable studies (7 out of 79) severely limits generalizability. High heterogeneity in the NHB mortality and chemotherapy analyses suggests that differences in study design, populations, and confounder adjustment drive much of the variability.
While the pooled data suggest a survival advantage for Hispanic males and a mortality disadvantage for NB males, the field still lacks the standardization and consistency needed to draw definitive conclusions about the interplay of race/ethnicity, treatment utilization, and AML survival.
By Farigol Hakem Zadeh, Ruben Ruiz Vega, M.D.”
To which Farigol Hakem Zadeh, Hematology and Medical Oncology Fellow, added:
“So grateful for your mentorship, Dr. Dina K..
Excited to see this work contribute to the conversation on equity in AML care.”
Title: Quantifying disparity: Race, socioeconomic status, and survival disparities in AML
Authors: Farigol Hakem Zadeh, Ruben Ruiz Vega, Dina Khalaf
Other articles featuring Farigol Hakem Zadeh and Dina Khalaf on OncoDaily.